PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time...
Covered in this story
What has happened since
- PTC Inc. is up 43.4% since this was published, 31 days ago.
- Ptc Therapeutics Inc is down 3.4% since this was published, 31 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on PTC Inc.
- BMO Capital Markets: $192 → $205 by Oct 2027 · Market Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PTC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on PTC Inc. →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.